Financial PerformanceAnalyst expects Befesa's annualized free cash flow to yield 5%, with EBITDA projections of €195-235m bolstered by lower zinc treatment costs and favorable hedging strategies.
Operational EfficiencyBefesa is poised for operational advancements in the US and China, which, along with the normalization of coke prices, is likely to contribute to a solid recovery and improved financial outcomes.
ValuationThe risk-reward profile for Befesa has improved following a sharp decline in its share price, making its valuation more appealing with shares now trading at a multiple of 7x EV/normalised EBITDA.